Latest Articles about VICL

Vical's Loss Narrower than Expected - Analyst Blog

Zacks Equity Research — Sat, 09 Feb 2013 02:22:01 Z

Vical Inc. ( VICL ) suffered a net loss per share of 9 cents in the fourth quarter of 2012, narrower than the Zacks Consensus Estimate of a loss of 10 cents per share but flat year over

Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI

gurujk — Mon, 21 Jan 2013 21:16:10 Z

According to GuruFocus Insider Data , these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: Vical Incorporated ( VICL ):

Vical Inc. Insiders Boost Shares after Company's NASDAQ Listing Gets Upgrade

Dianne Tordillo — Fri, 18 Jan 2013 05:14:43 Z

Insiders of biopharmaceutical products company Vical Inc. ( VICL ) have announced purchasing a combined amount of more than 133,000 shares between three people, reported last week on

Vical and Bristol-Myers Ink Deal - Analyst Blog

Zacks Equity Research — Mon, 17 Sep 2012 23:33:59 Z

Vical Incorporated ( VICL ) recently signed an agreement with Bristol-Myers Squibb Company ( BMY ) providing the latter with a global, non-exclusive license to its patented platform DNA

Abbott-Astellas Collaborate - Analyst Blog

Zacks Equity Research — Fri, 14 Sep 2012 02:34:20 Z

Abbott Laboratories ( ABT ) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). TransVax, a

Pre-Market Most Active for Sep 13, 2012 : CTL, AEO, HK, SIRI, BAC, NOK, ABB, VOD, FB, AAPL, VICL, QQQ

NASDAQ.com News — Thu, 13 Sep 2012 16:39:59 Z

The NASDAQ 100 Pre-Market Indicator is up 3.11 to 2,794.79. The total Pre-Market volume is currently 10,232,510 shares traded. The following are the most active stocks for the pre-market

Buyers take another dose of Vical

David Russell — Thu, 29 Dec 2011 14:12:42 Z

Option traders are betting that Vical has more room to run. optionMONSTER's Heat Seeker monitoring program detected the purchase of about 2,600 February 5 calls against open interest of

Looking for Value in September's Biggest Losers

David Sterman — Mon, 04 Oct 2010 19:42:56 Z

With reward comes risk. That's the painful lesson learned by biotech investors last month. Investors in Arena Pharma (Nasdaq: ARNA) , Idenix Pharma (Nasdaq: IDIX) , AMAG Pharma (Nasdaq: